

This is intended for US health care professionals only.

VyvansePro.com

*Learn how to use the Formulary
Look-up Tool for Vyvanse®
(lisdexamfetamine dimesylate)*

INDICATION

Vyvanse is indicated for the treatment of ADHD in patients ages 6 and above.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

- **CNS stimulants (amphetamines and methylphenidate-containing products) have a high potential for abuse and dependence.**
- **Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.**

Please [click here](#) for Full Prescribing Information.



Important Safety Information (continued)

- Contraindications
 - Known hypersensitivity to amphetamines or other ingredients in Vyvanse. Anaphylactic reactions, Stevens-Johnson syndrome, angioedema, and urticaria have been observed in postmarketing reports.
 - Concurrent administration of monoamine oxidase inhibitors (MAOI) or administration of Vyvanse within 14 days of the last MAOI dose. Hypertensive crisis can occur.
- Educate patients about abuse and periodically re-evaluate the need for Vyvanse.
- Sudden death, stroke and myocardial infarction have been reported in adults with CNS stimulant treatment at recommended doses. Sudden death has been reported in children and adolescents with structural cardiac abnormalities and other serious heart problems taking CNS stimulants at recommended doses for ADHD. Prior to treatment assess for the presence of cardiac disease. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during Vyvanse treatment.
- CNS stimulants cause an increase in blood pressure (mean increase about 2-4 mm Hg) and heart rate (mean increase about 3-6 bpm). Monitor all patients for tachycardia and hypertension.
- Use of stimulants may cause psychotic or manic symptoms in patients with no prior history, or exacerbation of symptoms in patients with preexisting psychosis. Clinical evaluation for bipolar disorder is recommended prior to stimulant use.

Please [click here](#) for Full Prescribing Information.



Important Safety Information (continued)


- CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Monitor weight and height in children during treatment with Vyvanse. Treatment may need to be interrupted in children not growing as expected.
- Stimulants used to treat ADHD, including Vyvanse, are associated with peripheral vasculopathy, including Raynaud's phenomenon. Careful observation for digital changes (e.g., numbness, pain, skin color change, or sensitivity to temperature, and rarely ulcerations and/or soft tissue breakdown) is necessary during treatment and may require further evaluation (e.g., referral).
- The most common adverse reactions ($\geq 5\%$ and at least twice the rate of placebo) reported in clinical trials were:
 - *Children aged 6 to 12*: decreased appetite, insomnia, upper abdominal pain, irritability, vomiting, decreased weight, nausea, dry mouth and dizziness;
 - *Adolescents aged 13 to 17*: decreased appetite, insomnia, and decreased weight;
 - *Adults*: decreased appetite, insomnia, dry mouth, diarrhea, nausea, anxiety and anorexia.

Please [click here](#) for Full Prescribing Information.



Formulary Coverage by Health Plan

- Health plans make a range of medications available to patients through the use of prescription drug formularies
- The 3 categories of formulary coverage for prescription drugs illustrated in this tool are:



VyvancePro.com provides current formulary information to help answer your Vyvance coverage questions. Check patient's individual health plan coverage and costs as plan status may change without notice. The following slides detail use of the VyvancePro.com Formulary Look-up Tool.

Please [click here](#) for Full Prescribing Information.

1. Hoadley J. *Is the U.S. Department of Veterans Affairs (VA) Meeting the Pharmaceutical Needs of Veterans? An Examination of the VA National Formulary, Issues of Patient Safety, and Management of the Pharmacy Benefits Program.* Washington, DC: House Committee on Veterans' Affairs; US House of Representatives; 2010. <http://www.gpo.gov/fdsys/pkg/CHRG-111hhrg53427/html/CHRG-111hhrg53427.htm> 10/5/2011 10:37:46 AM. Accessed October 5, 2011. 2. Hoadley J, Summer L, Hargrave E, Cubanski J, Neuman T. *A Comparison of PDPs Offering Basic and Enhanced Benefits.* Menlo Park, CA: The Henry J. Kaiser Family Foundation. *Medicare Part D 2010 Data Spotlight.* Published December 2009. 3. Mullins CD, Palumbo FB, Saba M. Formulary tier placement for commonly prescribed branded drugs: benchmarking and creation of a preferred placement index. *Am J Manag Care.* 2007;13(6, pt 2):377-384.



How to Use the Formulary Look-up Tool: Searching for a Health Plan

VyvancePro.com helps you find formulary coverage and co-pay information for your patients by health plan.*

You may find a plan's

- Tier status for Vyvance
- Vyvance co-pay information
- Health plan contact information
- Health plan PA form, if required

First, choose a state

Then, choose the coverage type and health plan

Vyvance® (lisdexamfetamine dimesylate) is indicated for the treatment of ADHD in patients ages 6 and above.

Formulary Coverage

Look up Vyvance Coverage and Co-pay Information

Select state and coverage type

State: Alabama

Coverage type: Commercial

Select health plan provider

Health plan provider: Select One

- Select One
- Aetna
- AmWINS Group Benefits
- Blue Cross and Blue Shield of Alabama
- Board of Pensions of the Presbyterian Church
- Boeing
- CarMax
- Catamaran
- Cigna
- Citigroup
- CVS/Caremark
- Delta Air Lines
- EliteCare
- Emdeon
- Enterprise Rent-A-Car
- Envision Rx Options
- Express Scripts
- Federal Employee Program
- FedEx
- Ford Motor Company

Check patient's individual health notice.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

- CNS stimulants (amphetamines and methylphenidate-containing products) have a high potential for abuse.
- Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence.

• Contraindications:

- Known hypersensitivity to amphetamines or other ingredients in Vyvance. Anaphylaxis, angioedema, and urticaria have been observed in postmarketing reports.
- Concurrent administration of monoamine oxidase inhibitors (MAOI) or administration of Vyvance within 14 days of the last MAOI dose. Hypertensive crisis can occur.

• Educate patients about abuse and periodically re-evaluate the need for Vyvance.

Check patient's individual health plan as plan status and coverage may change without notice.

*Current formulary and co-pay data are provided by Fingertip Formulary®.

Note: Health plan information may not always be available.

Please [click here](#) for Full Prescribing Information.



How to Use the Formulary Look-up Tool: Viewing the Results

Results: Once you make your selections, a results section appears with the health plan name, tier status, co-pay information, available health plan contact information, and restrictions (if applicable).

Vyvanse® (lisdexamfetamine dimesylate) is indicated for the treatment of ADHD in patients ages 6 and above. Updates

Formulary Coverage

National overview*

- Covered on Tier 2 or 3 for over 90% of commercially insured patients
- Average Tier 2 co-pay of less than \$30
- Over 80% of commercially insured patients have access on Tier 2

Learn more about formulary coverage and this tool

DOWNLOAD

Look up Vyvanse Coverage and Co-pay Information

Select state and coverage type

State:

Coverage type:

Select health plan provider

Health plan provider:

Select health plan (optional)

Health plan:

Formulary results* for AL

Health plan provider:	Co-pay:
Aetna	\$20.00 - \$45.00
Available health plan information:	Status:
800.414.2386	Tier 2
Prior Authorization Form	

Check patient's individual health plan coverage and costs as plan status may change without notice.

*Results data are provided by Fingertip Formulary® as of 9/5/2014.

Tier (Tier#) = A formulary category that determines the amount of co-pay required for a

Check patient's individual health plan as plan status and coverage may change without notice.

Please [click here](#) for Full Prescribing Information.



How to Use the Formulary Look-up Tool: Understanding the Results

Here's a closer look at how results will appear once you select a plan.

Select health plan (optional)

Health plan:

Formulary results* for **AL**

Health plan provider:	Co-pay:
Aetna	\$20.00 - \$45.00
Available health plan information:	Status:
800.414.2386	Tier 2

[Prior Authorization Form](#)

Populates with the health plan you selected, tier status, co-pay information, and health plan contact information, if available

If the plan you selected requires a PA for Vyvanse, a link may be provided to access the health plan's PA form

Check patient's individual health plan as plan status and coverage may change without notice.

Please [click here](#) for Full Prescribing Information.



Summary

VyvansePro.com

A resource for looking up Vyvanse (lisdexamfetamine dimesylate) formulary coverage and co-pay information by health plan for your patients.

INDICATION

Vyvanse is indicated for the treatment of ADHD in patients ages 6 and above.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

- **CNS stimulants (amphetamines and methylphenidate-containing products) have a high potential for abuse and dependence.**
- **Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.**

Please [click here](#) for Full Prescribing Information.

